Genomed Spólka Akcyjna Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Genomed Spólka Akcyjna's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 3.4% per year. Genomed Spólka Akcyjna's return on equity is 6.4%, and it has net margins of 2.7%.
Anahtar bilgiler
-9.2%
Kazanç büyüme oranı
-9.2%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 56.3% |
| Gelir büyüme oranı | 3.4% |
| Özkaynak getirisi | 6.4% |
| Net Marj | 2.7% |
| Sonraki Kazanç Güncellemesi | 13 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Genomed Spólka Akcyjna nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 22 | 1 | 12 | 0 |
| 31 Mar 24 | 22 | 1 | 11 | 0 |
| 31 Dec 23 | 22 | 1 | 11 | 0 |
| 30 Sep 23 | 21 | 0 | 11 | 0 |
| 30 Jun 23 | 21 | 0 | 11 | 0 |
| 31 Mar 23 | 21 | 0 | 11 | 0 |
| 31 Dec 22 | 20 | 0 | 10 | 0 |
| 30 Sep 22 | 20 | 1 | 10 | 0 |
| 30 Jun 22 | 20 | 1 | 11 | 0 |
| 31 Mar 22 | 20 | 2 | 10 | 0 |
| 31 Dec 21 | 20 | 1 | 10 | 0 |
| 30 Sep 21 | 20 | 1 | 10 | 0 |
| 30 Jun 21 | 20 | 1 | 10 | 0 |
| 31 Mar 21 | 19 | 0 | 10 | 0 |
| 31 Dec 20 | 19 | 0 | 10 | 0 |
| 30 Sep 20 | 19 | 0 | 10 | 0 |
| 30 Jun 20 | 19 | 1 | 10 | 0 |
| 31 Mar 20 | 20 | 1 | 11 | 0 |
| 31 Dec 19 | 20 | 1 | 11 | 0 |
| 30 Sep 19 | 19 | 1 | 11 | 0 |
| 30 Jun 19 | 19 | 1 | 11 | 0 |
| 31 Mar 19 | 18 | 1 | 10 | 0 |
| 31 Dec 18 | 19 | 1 | 10 | 0 |
| 30 Sep 18 | 18 | 2 | 9 | 0 |
| 30 Jun 18 | 17 | 2 | 8 | 0 |
| 31 Mar 18 | 17 | 2 | 8 | 0 |
| 31 Dec 17 | 16 | 2 | 8 | 0 |
| 30 Sep 17 | 16 | 1 | 9 | 0 |
| 30 Jun 17 | 16 | 1 | 9 | 0 |
| 31 Mar 17 | 15 | 0 | 9 | 0 |
| 31 Dec 16 | 14 | 0 | 9 | 0 |
| 30 Sep 16 | 14 | 1 | 8 | 0 |
| 30 Jun 16 | 12 | 1 | 7 | 0 |
| 31 Mar 16 | 11 | 0 | 7 | 0 |
| 31 Dec 15 | 10 | 0 | 7 | 0 |
| 30 Sep 15 | 9 | 0 | 7 | 0 |
| 30 Jun 15 | 8 | 0 | 7 | 0 |
| 31 Mar 15 | 8 | 0 | 6 | 0 |
| 31 Dec 14 | 7 | 0 | 6 | 0 |
| 30 Sep 14 | 6 | 0 | 6 | 0 |
| 30 Jun 14 | 6 | 0 | 5 | 0 |
| 31 Mar 14 | 5 | 0 | 5 | 0 |
| 31 Dec 13 | 5 | 0 | 4 | 0 |
Kaliteli Kazançlar: GEN has high quality earnings.
Büyüyen Kar Marjı: GEN's current net profit margins (2.7%) are higher than last year (1.3%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: GEN's earnings have declined by 9.2% per year over the past 5 years.
Büyüme Hızlandırma: GEN's earnings growth over the past year (113.5%) exceeds its 5-year average (-9.2% per year).
Kazançlar vs. Sektör: GEN earnings growth over the past year (113.5%) exceeded the Biotechs industry -20.8%.
Özkaynak Getirisi
Yüksek ROE: GEN's Return on Equity (6.4%) is considered low.